Information  X 
Enter a valid email address

Uniphar PLC (UPR)

  Print      Mail a friend

Wednesday 21 August, 2019

Uniphar PLC

Notice of Interim Results

RNS Number : 7005J
Uniphar PLC
21 August 2019
 

 

 

 

 

Uniphar plc

 

Notice of Interim Results

 

 

Dublin, London, 21 August 2019: Uniphar plc (the "Company" or the "Group"), a diversified healthcare services provider, will announce its interim results for the half year ended 30 June 2019 at 07:00 am (GMT) on Tuesday 17 September 2019.

 

A conference call for analysts and investors will be held at 9.00 am (GMT) on the day to discuss the Group's interim results. Analysts and investors who wish to participate should visit https://www.uniphar.ie/cms/investors to register.

 

The Company's half year results press release and presentation will be available on the website at 07.00 am (GMT) on 17 September 2019 at www.uniphar.ie.

 

--- ENDS ---

 

For further details contact:

 

Uniphar                                                                                   

 

Brian O'Shaughnessy

Director of Investor Relations and Corporate Development

 

+353 (0) 1 428 7777

 

 

[email protected]

 

 

Davy

(Joint Broker, Nominated Adviser and Euronext

Growth Adviser)          

 

Fergal Meegan

Barry Murphy

Tom Tynan

 

+353 (0) 1 679 6363

RBC Capital Markets (Joint Broker)                                                                  

Darrell Uden

Jonathan Hardy

Thomas Debrosse

 

+44 (0) 20 7653 4000

Q4 PR

(Public Relations Adviser to Uniphar)                                      

 

Iarla Mongey

 

 

+353 (0) 1 475 1444

or

+353 87 235 6461

 

About Uniphar plc

 

Headquartered in Dublin, Ireland, Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access, and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK, the Benelux and the US.

 

In Commercial & Clinical, the Group provides sales, marketing and distribution solutions to pharmaceutical and medical devices manufacturers on an outsourced basis.

 

In Product Access, the Group is growing two distinct service offerings: 1) sourcing and supplying unlicensed medicines to meet the needs of pharmacy customers (On-Demand Access); and 2) managing the release of speciality medicines for pharmaceutical manufacturers to specifically approved patient populations (Exclusive Access).

 

Supply Chain & Retail is an Irish only business for the Group, with Uniphar being an established market leader in Ireland with c.50% of the wholesale market servicing retail pharmacy, supported by a network of 235 owned and franchised pharmacies.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORBCGDISXDBGCG

a d v e r t i s e m e n t